TSS
CMPX icon

Two Sigma Securities’s Compass Therapeutics CMPX Stock Holding History

Two Sigma Securities’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,887
Closed -$20.1K – 1562
2024
Q4 		$20.1K Buy
+13,887
New +$23.1K ﹤0.01% 1319

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Two Sigma Securities's CMPX Position: Q1 2025 in Review

Two Sigma Securities sold out of Compass Therapeutics (CMPX) in Q1 2025, closing a stake of 13,887 shares — an estimated $20.1K sold.

Two Sigma Securities first reported a position in CMPX in Q4 2024 and held it in 1 quarter. The position peaked at $20.1K in Q4 2024. 108 funds tracked by Wall St. Rank hold CMPX as of Q1 2025.

  • Two Sigma Securities reported no remaining Compass Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Securities sold 13,887 Compass Therapeutics shares in Q1 2025, an estimated $20.1K.
  • Two Sigma Securities first reported a position in Compass Therapeutics in Q4 2024 and held it in 1 quarter.
  • Two Sigma Securities's Compass Therapeutics position peaked at $20.1K in Q4 2024.
  • 108 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2025.

Based on Two Sigma Securities's 13F filing for Q1 2025, filed 15 May 2025.